Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.OSE Immunotherapeutics has reported positive data from preclinical and human ex-vivo studies of its Covid-19 vaccine candidate, CoVepiT.
The company published the findings online on BioRxiv. Based on optimised peptides improved with artificial intelligence algorithms, CoVepiT elicits a lasting sentinel T lymphocyte immune response against Covid-19.